About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

Citation:

European Cardiology Review 2017;12(2):88

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Citation:

European Cardiology Review 2017;12(2):96.

Optical Coherence Tomography For the Detection of the Vulnerable Plaque

Citation:

European Cardiology Review 2016;11(2):90–5

Antiplatelet Therapy in Acute Coronary Syndrome

Citation:

European Cardiology Review 2017;12(1):33–7.